[Frontiers in Bioscience 18, 765-772, January 1, 2013]

Human monoclonal antibodies in cancer therapy: a review of recent developments

Lin Xin1, Jiaqing Cao1, Hua Cheng1, Fei Zeng1, Xiaoyun Hu1, Jianghua Shao1

1Department of General Surgery, The Second Affiliated Hospital of NanChang University, 330006 Nanchang, Jiangxi, China


1. Abstract
2. Introduction
3. Novel methods of human monoclonal antibody production developed in the last decade
4. Generation of novel human monoclonal antibodies
4.1. Targets in apoptosis
4.2. Targets in angiogenesis
4.3. Insulin-like growth factor I receptor as a target
4.4. Targets in hepatocyte growth factor-mediated signaling
4.5. Targets in solid tumors
5. Human monoclonal antibodies and cytotoxic activity
6. Clinical application of monoclonal antibodies in the last decade
7. Conclusion
8. Acknowledgments
9. References


In the last decade, phage-display technology for the generation of monoclonal antibodies (mAbs) has improved significantly. Several novel human mAbs directed to a wide range of targets have been generated for the treatment of common malignancies. These targets include antigens associated with apoptosis, angiogenesis and solid tumors, as well as tumor growth-related antigens, insulin-like growth factor I receptor and hepatocyte growth factor. The safety, pharmacokinetics, and pharmacodynamics of several human mAbs have been evaluated in patients with advanced solid tumors. In conclusion, significant advances in the generation and application of human mAbs in cancer therapy have been made in the last decade.